Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine

L. Pazdera, MR. Sperling, JH. Harvey, MC. Sam, LA. Strom, D. Blum, T. Grinnell, H. Cheng,

. 2018 ; 59 (3) : 704-714. [pub] 20180216

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19000916

OBJECTIVE: To evaluate the influence of prior use of carbamazepine (CBZ) and other antiepileptic drugs (AEDs) with a putatively similar mechanism of action (inhibition of voltage-gated sodium channels; VGSCs) on seizure outcomes and tolerability when converting to eslicarbazepine acetate (ESL), using data pooled from 2 controlled conversion-to-ESL monotherapy trials (studies: 093-045, 093-046). METHODS: Adults with treatment-resistant focal (partial-onset) seizures were randomized 2:1 to ESL 1600 or 1200 mg once daily. The primary efficacy endpoint was study exit (meeting predefined exit criteria related to worsening seizure control) versus an historical control group. Other endpoints included change in seizure frequency, responder rate, and tolerability. Endpoints were analyzed for subgroups of patients who received CBZ (or any VGSC inhibitor [VGSCi]) during baseline versus those who received other AEDs. RESULTS: Of 365 patients in the studies, 332 were evaluable for efficacy. The higher risk of study exit in the subgroups that received CBZ (or any VGSCi) during baseline, versus other AEDs, was not statistically significant (hazard ratios were 1.49 for +CBZ vs -CBZ [P = .10] and 1.27 for +VGSCi vs. -VGSCi [P = .33]). Reductions in seizure frequency and responder rates were lower in patients who converted from CBZ or other VGSCi compared with those who converted from other AEDs. There were no notable differences in overall tolerability between subgroups, but the incidence of some adverse events (eg, dizziness, somnolence, nausea) differed between subgroups and/or between treatment periods. SIGNIFICANCE: Baseline use of CBZ or other major putative VGSC inhibitors did not appear to significantly increase the risk of study exit due to worsening seizure control, or to increase the frequency of side effects when converting to ESL monotherapy. However, bigger improvements in efficacy may be possible in patients converting to ESL monotherapy from an AED regimen that does not include a VGSC inhibitor.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000916
003      
CZ-PrNML
005      
20190118110258.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/epi.14014 $2 doi
035    __
$a (PubMed)29450890
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pazdera, Ladislav $u Vestra Clinics, Rychnov nad Kneznou, Czech Republic.
245    10
$a Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine / $c L. Pazdera, MR. Sperling, JH. Harvey, MC. Sam, LA. Strom, D. Blum, T. Grinnell, H. Cheng,
520    9_
$a OBJECTIVE: To evaluate the influence of prior use of carbamazepine (CBZ) and other antiepileptic drugs (AEDs) with a putatively similar mechanism of action (inhibition of voltage-gated sodium channels; VGSCs) on seizure outcomes and tolerability when converting to eslicarbazepine acetate (ESL), using data pooled from 2 controlled conversion-to-ESL monotherapy trials (studies: 093-045, 093-046). METHODS: Adults with treatment-resistant focal (partial-onset) seizures were randomized 2:1 to ESL 1600 or 1200 mg once daily. The primary efficacy endpoint was study exit (meeting predefined exit criteria related to worsening seizure control) versus an historical control group. Other endpoints included change in seizure frequency, responder rate, and tolerability. Endpoints were analyzed for subgroups of patients who received CBZ (or any VGSC inhibitor [VGSCi]) during baseline versus those who received other AEDs. RESULTS: Of 365 patients in the studies, 332 were evaluable for efficacy. The higher risk of study exit in the subgroups that received CBZ (or any VGSCi) during baseline, versus other AEDs, was not statistically significant (hazard ratios were 1.49 for +CBZ vs -CBZ [P = .10] and 1.27 for +VGSCi vs. -VGSCi [P = .33]). Reductions in seizure frequency and responder rates were lower in patients who converted from CBZ or other VGSCi compared with those who converted from other AEDs. There were no notable differences in overall tolerability between subgroups, but the incidence of some adverse events (eg, dizziness, somnolence, nausea) differed between subgroups and/or between treatment periods. SIGNIFICANCE: Baseline use of CBZ or other major putative VGSC inhibitors did not appear to significantly increase the risk of study exit due to worsening seizure control, or to increase the frequency of side effects when converting to ESL monotherapy. However, bigger improvements in efficacy may be possible in patients converting to ESL monotherapy from an AED regimen that does not include a VGSC inhibitor.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antikonvulziva $x aplikace a dávkování $x škodlivé účinky $7 D000927
650    _2
$a karbamazepin $x aplikace a dávkování $x škodlivé účinky $7 D002220
650    _2
$a dibenzazepiny $x aplikace a dávkování $x škodlivé účinky $7 D003984
650    _2
$a refrakterní epilepsie $x diagnóza $x farmakoterapie $7 D000069279
650    _2
$a náhrada léků $x škodlivé účinky $x trendy $7 D057915
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nauzea $x chemicky indukované $x diagnóza $7 D009325
650    _2
$a výsledek terapie $7 D016896
650    _2
$a blokátory sodíkových kanálů řízených napětím $x aplikace a dávkování $x škodlivé účinky $7 D061567
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sperling, Michael R $u Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
700    1_
$a Harvey, Jay H $u Division of Epilepsy, Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, USA.
700    1_
$a Sam, Maria C $u Wake Forest School of Medicine, Winston Salem, NC, USA.
700    1_
$a Strom, Laura A $u University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
700    1_
$a Blum, David $u Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
700    1_
$a Grinnell, Todd $u Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
700    1_
$a Cheng, Hailong $u Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
773    0_
$w MED00001567 $t Epilepsia $x 1528-1167 $g Roč. 59, č. 3 (2018), s. 704-714
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29450890 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190118110513 $b ABA008
999    __
$a ok $b bmc $g 1363952 $s 1039039
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 59 $c 3 $d 704-714 $e 20180216 $i 1528-1167 $m Epilepsia $n Epilepsia $x MED00001567
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options